News

According to a study, a newly synthesized compound kills a range of hard-to-treat cancer types by targeting a previously unexploited vulnerability.

Researchers have used genetic data from 1.4 million people of diverse ancestry across sub-Saharan Africa to investigate how the use of diverse and representative data can impact our ability to predict risk of disease.

A randomized clinical trial found that a combination of immunotherapy and chemotherapy treatment boosted the one-year survival rate of pancreatic cancer by over 60%.

Late-breaking research from Cedars-Sinai Cancer finds an immunotherapy drug combination in Phase II clinical trials improves survival for patients with immunotherapy-resistant, non-small cell lung cancer.

Scientists have identified a receptor, known as BASP1, that is capable of binding cocaine at very low doses.

A repurposed FDA-approved drug combined with a novel drug carrier could be used to target microglia and treat neuroinflammatory diseases.

In a study, genetically engineered immune cells successfully targeted the specific cancer cells that may be responsible for the relapse of acute myeloid leukemia.

Replicating the human blood–brain barrier has enabled the development of drug-carrying nanoparticles that can enter the brain more easily, potentially making brain cancers easier to treat.

Researchers have long suspected that interleukin-12 could be a powerful cancer treatment, but it can cause unwanted adverse effects. Now, researchers have developed a version of the molecule that remains inactive until it reaches the tumor site.

The NIH has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.